Physician profile
Laura Dember
NPI 1144285370
$109,741.11
in general payments reported to CMS, 2019-2025
8 companies · $32K in 2025
The $32K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $750 · 2021: $3,000 · 2022: $6,858 · 2023: $15K · 2024: $41K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $89K · Food and Beverage: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $88,765.05 |
| Food and Beverage | $100.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $53,815.07 | 2022-2025 | |
| Csl Behring | $35,000.00 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $9,430.87 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $6,590.95 | 2021-2024 | Lokelma |
| Glaxosmithkline, LLC. | $4,887.50 | 2019-2023 | |
| Cook Medical LLC | $16.72 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Dember listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.